MetFlux Research

What MetFlux Research does

MetFlux Research Pvt. Ltd. is a Mumbai-headquartered (with primary operations in Bengaluru and a US office in Boston) systems physiology company founded in 2017. It builds structured computational models that treat disease as system-level drift rather than isolated biomarker dysfunction, and translates those models into deployable precision health systems for chronic and aging-linked conditions. The company operates an integrated three-platform architecture: ΩmeX (systems modeling layer encoding physiological structure across scales), MetSolve (translational modeling engine for R&D validation and endpoint structuring), and MetSights (clinical interpretation layer for precision-care deployment), supplemented by the Ωmega Initiative, an independent scientific mission founded by Prof. K V Venkatesh.

The business model is B2B enterprise R&D partnerships with nutraceutical, biopharma, medical nutrition, and consumer-goods organizations. Revenue is generated through targeted mechanism validation, embedded R&D partnerships, strategic co-development, and milestone/royalty-linked arrangements, with potential upside from platform licensing of the MetSights intelligence layer. Named customers include The Himalaya Drug Company, Amway, Hindustan Unilever, Mondelēz International, and Zydus Wellness; academic advisory relationships span IIT Bombay, IISc Bengaluru, and IIT Madras.

The team is lean (11–50 employees) and founder-led, with Prof. K V Venkatesh (IIT Bombay) as Founder & Chief Scientist, Suryaprakash K V as Managing Partner, and Karan Lomore as Director of Platform Engineering. Scientific credibility is anchored by ten peer-reviewed publications spanning 2013–2026 in journals including Scientific Reports, RSC Advances, npj Systems Biology and Applications, JID, PLOS One, and Computers in Biology and Medicine, with externally validated assets such as the MASLD Risk Score (AUROC 0.91 on NHANES, 0.85 on clinical cohort).

Name

MetFlux Research

Legal name

MetFlux Research Pvt. Ltd.

Website

https://metflux.in

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

MetFlux Research is a Mumbai- and Bengaluru-based systems physiology company that builds computational models (ΩmeX, MetSolve, MetSights) to translate biological mechanisms into precision health R&D partnerships and clinical deployment for nutraceutical, biopharma, and consumer-goods enterprises globally.

Ownership category

akta.pro rank

Product category

Computational Systems Biology Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Computer Systems Design and Related Services (54151), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372), Services-Management Consulting Services (8742)

akta.pro industry

PRIMARYHLAGAJAO

AI/ML Platforms for Drug Discovery & Experiment Optimization

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

SECONDARYHLAGAJAF

Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

SECONDARYHLAGAJAM

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

• Systems physiology modeling
• Translational biology software
• Precision health platforms
• Computational biomarker analysis
• Pathway modeling services

Headquarters

HQ city

Bengaluru

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. R&D Partnership and Co-development Services: Revenue generated through targeted mechanism validation, embedded R&D partnership, and strategic co-development models with nutraceutical, biopharma, and medical nutrition teams. Engagement structures include milestone and royalty-linked arrangements.
2. Platform Licensing and Deployment: Potential revenue from deploying MetSights intelligence layer and computational frameworks to precision wellness programs and clinical systems, including automated physiological reporting and structured clinical interpretation.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

MetFlux Research builds structured systems physiology models and translational infrastructure that connect biological mechanisms to precision health systems for chronic and aging-linked conditions. Its offering is delivered through three integrated platforms: ΩmeX (systems modeling architecture), MetSolve (translational modeling engine for R&D and endpoint strategy), and MetSights (clinical systems interpretation layer for precision care). The company monetizes these capabilities through embedded R&D partnerships, strategic co-development, and platform deployment to enterprise clients in nutraceutical, biopharma, and medical nutrition.

Differentiator

Problem solved

Functional benefit

Brands

• ΩmeX: Systems Modeling Architecture - computational framework that encodes physiological structure across scales enabling mechanistic reasoning over biological transitions
• MetSolve
• MetSights
• Ωmega Initiative

Products and services

• ΩmeX (OmegaX)
• MetSolve
• MetSights
• R&D Partnership and Co-Development Services

Quantifiable outcome

• MASLD Risk Score (MRS) validated with AUROC 0.91 on NHANES dataset and 0.85 on clinical cohort for non-invasive MASLD screening and severity grading
• +2 more outcomes

Named customers5 records

Segments10 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core.

• The Himalaya Drug CompanycoreStrategic or Co-development PartnerTranslational partnership with pharmaceutical company for systems physiology-based research and precision health applications. Collaboration focused on connecting biological mechanisms to deployable health solutions.
• AmwaycoreStrategic or Co-development PartnerCollaborative R&D partnership with global health and wellness company for nutraceutical formulation modeling and intervention analysis. Partnership leverages MetSolve translational modeling capabilities.
• Hindustan Unilever LimitedcoreStrategic or Co-development PartnerStrategic partnership with consumer goods conglomerate for metabolic and health technology applications. Collaboration in formulation optimization and clinical endpoint structuring.
• Mondelēz InternationalcoreStrategic or Co-development PartnerResearch collaboration focused on nutrition and health outcomes modeling. Partnership involves population-level simulation and intervention response analysis.
• Zydus WellnesscoreStrategic or Co-development PartnerTranslational partnership for wellness and health technology development. Collaboration enables structured translational reasoning from pathway logic to implementable precision health strategies.
• IIT Bombay (Indian Institute of Technology Bombay)coreStrategic or Co-development PartnerAcademic advisory relationship through Prof. Sharad Bhartiya (Department of Chemical Engineering) and founding architect involvement of Prof. K V Venkatesh. Enables cross-institutional scientific dialogue and expert exchange.
• IISc Bengaluru (Indian Institute of Science)coreStrategic or Co-development PartnerAcademic advisory relationship through Prof. Narendra Dixit (Department of Bioengineering). Supports foundational systems physiology research and academic-clinical engagement.
• IIT Madras (Indian Institute of Technology Madras)coreStrategic or Co-development PartnerAcademic advisory relationship through Prof. Karthikeyan (Department of Biotechnology). Contributes to multi-scale connected pathway modeling and translational research capabilities.
• Ωmega InitiativecoreStrategic or Co-development PartnerΩmega is a scientific initiative founded by Prof. K V Venkatesh to advance systems physiology as a foundational lens in medicine. MetFlux enables applied translation and real-world implementation of Ωmega's research frameworks. The initiative is collaboration-first and independent in mission.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• CytoReason: Computational disease models used by pharma R&D teams for target discovery and translational decision-making. Direct overlap with MetSolve's translational modeling for biopharma customers.
• GNS Healthcare: Applies causal AI and simulation models to biomedical and pharmaceutical R&D, mirroring MetFlux's systems-modeling approach for mechanism discovery and intervention simulation. Closest analog in the 'models-as-platform' positioning.

Emerging players

• Causaly: AI platform for scientific literature and biomedical knowledge modeling to support drug discovery and R&D. Comparable on systems-level scientific reasoning applied to translational research.
• Insitro: Combines ML, high-throughput biology, and disease modeling for drug discovery. Comparable in combining computational modeling with translational R&D applications, though operating at much larger scale.
• Q Bio: Precision health platform integrating multi-modal data (imaging, clinical, lab) for individual health assessments. Comparable on the MetSights vision of multi-modal integration for precision health, though focused on clinical rather than R&D applications.
• Owkin: Uses AI/ML on multi-modal biomedical data to support pharma R&D and clinical research. Comparable on multi-modal data integration and translational modeling for biopharma.
• BioSymetrics: Applies systems biology, ML, and multi-omics modeling to precision medicine and R&D. Closely comparable in applying computational systems biology to chronic and metabolic disease research.

Broad incumbents

• Recursion Pharmaceuticals: Operates an integrated AI-driven biology and chemistry platform for drug discovery. Overlaps with MetFlux's multi-scale modeling philosophy but operates across drug discovery at a far broader and better-funded scale.
• Evotec: Global contract research and platform company offering computational biology, translational modeling, and R&D partnerships to pharma. Comparable as an established systems-biology-to-pharma services provider, but at vastly greater scale.

Others

• Nimbus Therapeutics: Computational drug design company using structure-based and systems modeling approaches. Adjacent in using modeling infrastructure for biopharma R&D, though focused on internal pipeline rather than R&D services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/metflux
• Facebookfacebook.com/MetFlux

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MetFlux Research